Business

Hikma Pharmaceuticals has signed an agreement with Glenmark Pharmaceuticals for exclusive US rights to Ryaltris olopatadine hydrochloride/mometasone furoate nasal spray for the treatment of seasonal allergic rhinitis, the companies said. According to the announcement, the deal includes an upfront payment, milestone payments, and royalties; the amounts were not … [Read more...] about Hikma to distribute Ryaltris nasal spray in the US

Aradigm Corporation, which filed for bankruptcy in February 2019, said that it will sell all of its assets related to Lipoquin inhaled ciprofloxacin, Apulmiq (Linhaliq) dual release inhaled ciprofloxacin, and other inhaled ciprofloxacin candidates to Grifols, subject to approval by the bankruptcy court. The deal also leaves Aradigm "free to accept higher and better … [Read more...] about Grifols agrees to acquire all assets related to Aradigm’s inhaled ciprofloxacin programs

Apollo Global Management has agreed to acquire Covis Pharma, which markets several ciclesonide aerosol products: the Alvesco MDI and Omnaris and Zetonna nasal sprays. Terms of the deal were not disclosed. Covis is currently owned by Cerberus Capital Management, which founded the company in 2011. In 2017, Covis acquired the US rights to the three ciclesonide … [Read more...] about Apollo Global Management agrees to acquire Covis Pharma

According to Novartis's 2019 annual report, Novartis subsidiary Sandoz has discontinued development of a generic version of the Advair Diskus fluticasone propionate/salmeterol DPI for the treatment of asthma and COPD for the US market as of January 2020. In October 2016, Sandoz filed a citizen petition with the FDA asking that the agency delay approval of any … [Read more...] about Sandoz has discontinued its US generic Advair Diskus program

Days after announcing that the FDA has accepted its NDA resubmission for Gimoti metoclopramide nasal spray for the treatment of diabetic gastroparesis, Evoke Pharma said that the company has cancelled a previously announced commercialization deal with Novus Growth Partners and has signed a new 5-year deal with Eversana for commercialization and distribution of Gimoti … [Read more...] about Evoke announces commercialization deal with Eversana for Gimoti nasal spray

Virpax Pharmaceuticals announced that it has acquired exclusive global rights from Nanomerics Ltd. for the use of molecular envelope technology (MET) for delivery of an intranasal formulation of enkephalin for the treatment of PTSD. The company says that PES200 will be delivered via a cartridge-based, pressurized nasal delivery device, presumably the Naltos dry … [Read more...] about Virpax to develop intranasal enkephalin formulation for the treatment of PTSD

Altavant Sciences has announced its acquisition of Onspira Therapeutics, which apparently had a single candidate in its pipeline: OSP-101, an inhaled interleukin-1 receptor antagonist. In August 2018, the FDA granted Orphan Drug designation to OSP-101 for the treatment of bronchiolitis obliterans syndrome (BOS). According to Altavant, the deal included an upfront … [Read more...] about Altavant Sciences acquires Onspira Therapeutics